Tenaya Therapeutics prices $60 million public offering amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2025
0mins
Source: Globenewswire
Tenaya Therapeutics Inc's stock fell by 35.29% today, crossing below the 5-day SMA, as the broader market faced declines with the Nasdaq-100 down 1.62% and the S&P 500 down 0.92%.
The decline in Tenaya's stock is attributed to its announcement of a $60 million public offering of 50 million units at $1.20 each, aimed at funding the development of its gene therapies TN-201 and TN-401. This offering reflects strong market interest, but the stock's performance is also impacted by the overall market weakness, suggesting sector rotation as investors reassess their positions.
The public offering is expected to close around December 15, 2025, and if successful, will provide essential funding to advance Tenaya's R&D projects. However, the stock's significant drop indicates investor caution amid the current market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNYA
Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.746
Low
2.00
Averages
9.14
High
40.00
Current: 0.746
Low
2.00
Averages
9.14
High
40.00
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- Executive Change: Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Hiro Higa, who will retire in Q3 2026; Hyllengren brings over 20 years of biotech finance experience and will oversee the company's financial strategy and capital allocation.
- Previous Experience: Most recently, Hyllengren served as CFO and Executive Vice President at Zura Bio Limited, and prior to that, he was CFO and COO at Atara Biotherapeutics, where he successfully led public financing activities and guided the company's organizational transformation.
- Transition Plan: Tenaya stated that Higa's retirement is unrelated to Hyllengren's appointment, and Higa will remain with the company as a consultant to facilitate the transition of finance and accounting responsibilities, ensuring continuity in operations.
- Stock Performance: Tenaya Therapeutics' stock has traded between $0.53 and $2.35 over the past year, closing at $0.73 on Monday with a 2.43% increase, although shares are trading down 0.76% to $0.72 in the overnight market, indicating that market reactions to the new CFO will need to be monitored.
See More
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- New CFO Appointment: Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer effective July 13, 2026, who will oversee financial strategy, capital allocation, and investor relations, expected to significantly support the company's strategic development in heart disease treatments.
- Extensive Industry Experience: Hyllengren brings over 20 years of experience in biotechnology finance, having served as CFO at Zura Bio and Atara Biotherapeutics, where he executed over $500 million in public financings, showcasing his strong background in capital markets.
- Advancing Clinical Trials: Tenaya is advancing its gene therapy projects for heart disease, and Hyllengren's expertise is anticipated to optimize capital allocation and support the company's performance in upcoming pivotal clinical trials, thereby creating long-term value for patients and shareholders.
- Executive Retirement and Transition: Concurrently, Tenaya announced the retirement of Senior Vice President of Finance Hiro Higa in the third quarter of 2026; although unrelated to Hyllengren's hiring, Higa will remain as a consultant to ensure a smooth transition of financial functions.
See More
Tenaya Therapeutics Reports Promising Interim Data on Gene Therapy for HCM
- Clinical Trial Progress: Tenaya Therapeutics presented interim data from the MyPEAK-1 trial, showing that all evaluable patients exhibited consistent signs of cardiac remodeling and symptom improvement, indicating the potential of TN-201 in treating MYBPC3-associated hypertrophic cardiomyopathy.
- Efficacy Assessment: As of the May 2026 data cutoff, six patients showed improvements across multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with two patients in the higher-dose cohort demonstrating enhanced exercise capacity.
- Long-term Effects: Benefits for Cohort 1 patients were sustained for up to two years, while Cohort 2 patients exhibited greater symptom relief and improved cardiac function at earlier time points, suggesting durable and dose-responsive effects of TN-201.
- Regulatory Progress: TN-201 has received PRIME designation from the European Medicines Agency and is included in the FDA's Rare Disease Evidence Principles process, with Tenaya planning to expand enrollment for further long-term outcome characterization, highlighting the company's strategic positioning in cardiac disease treatment.
See More
Tenaya Therapeutics Presents Interim Data on TN-201 Gene Therapy for HCM
- Clinical Trial Update: Tenaya Therapeutics is presenting new interim data from the MyPEAK-1 Phase 1b/2 trial for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, with a webcast scheduled for June 3, 2026, enhancing clinical transparency and investor confidence.
- Disease Context: MYBPC3-associated hypertrophic cardiomyopathy is the most common genetic form, accounting for about 20% of the 120,000 patients in the U.S., highlighting the widespread nature of the condition and its severe impact on patients' quality of life, with no effective treatments addressing its genetic cause.
- Therapeutic Mechanism: TN-201 is an AAV9-based gene therapy designed to deliver a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion, aiming to restore MyBP-C protein levels and potentially halt or reverse disease progression, which could have significant clinical implications.
- Market Performance: TNYA's stock has traded between $0.48 and $2.35 over the past year, closing at $0.79 on Tuesday with a 9.20% decline, while pre-market trading shows an increase to $0.84, up 6.33%, indicating market interest in its clinical advancements.
See More
Tenaya Therapeutics to Report Interim Data on TN-201 Gene Therapy for HCM
- Clinical Data Release: Tenaya Therapeutics will announce interim data from the MyPEAK™-1 trial on June 3, 2026, focusing on TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, potentially offering new treatment hope for 120,000 patients in the U.S.
- Live Webcast Event: The company will host a live webcast at 8:00 AM ET on the same day to review new data from MyPEAK™-1, allowing participants to register for access, thereby enhancing investor transparency and trust in the company's R&D progress.
- Disease Background: Variants in MYBPC3 are the leading genetic cause of hypertrophic cardiomyopathy, affecting approximately 20% of patients, leading to abnormal heart contraction and serious outcomes like heart failure and arrhythmias, indicating a strong market demand for TN-201.
- Therapy Design and Regulatory Progress: TN-201 is an AAV9-based gene therapy that has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug designations, highlighting its innovation and market potential in treating hypertrophic cardiomyopathy.
See More
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- Executive Change: Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, succeeding Hiro Higa, who will retire in Q3 2026; Hyllengren brings over 20 years of biotech finance experience and will oversee the company's financial strategy and capital allocation.
- Previous Experience: Most recently, Hyllengren served as CFO and Executive Vice President at Zura Bio Limited, and prior to that, he was CFO and COO at Atara Biotherapeutics, where he successfully led public financing activities and guided the company's organizational transformation.
- Transition Plan: Tenaya stated that Higa's retirement is unrelated to Hyllengren's appointment, and Higa will remain with the company as a consultant to facilitate the transition of finance and accounting responsibilities, ensuring continuity in operations.
- Stock Performance: Tenaya Therapeutics' stock has traded between $0.53 and $2.35 over the past year, closing at $0.73 on Monday with a 2.43% increase, although shares are trading down 0.76% to $0.72 in the overnight market, indicating that market reactions to the new CFO will need to be monitored.
See More
Tenaya Therapeutics Appoints New CFO Eric Hyllengren
- New CFO Appointment: Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer effective July 13, 2026, who will oversee financial strategy, capital allocation, and investor relations, expected to significantly support the company's strategic development in heart disease treatments.
- Extensive Industry Experience: Hyllengren brings over 20 years of experience in biotechnology finance, having served as CFO at Zura Bio and Atara Biotherapeutics, where he executed over $500 million in public financings, showcasing his strong background in capital markets.
- Advancing Clinical Trials: Tenaya is advancing its gene therapy projects for heart disease, and Hyllengren's expertise is anticipated to optimize capital allocation and support the company's performance in upcoming pivotal clinical trials, thereby creating long-term value for patients and shareholders.
- Executive Retirement and Transition: Concurrently, Tenaya announced the retirement of Senior Vice President of Finance Hiro Higa in the third quarter of 2026; although unrelated to Hyllengren's hiring, Higa will remain as a consultant to ensure a smooth transition of financial functions.
See More
Tenaya Therapeutics Reports Promising Interim Data on Gene Therapy for HCM
- Clinical Trial Progress: Tenaya Therapeutics presented interim data from the MyPEAK-1 trial, showing that all evaluable patients exhibited consistent signs of cardiac remodeling and symptom improvement, indicating the potential of TN-201 in treating MYBPC3-associated hypertrophic cardiomyopathy.
- Efficacy Assessment: As of the May 2026 data cutoff, six patients showed improvements across multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with two patients in the higher-dose cohort demonstrating enhanced exercise capacity.
- Long-term Effects: Benefits for Cohort 1 patients were sustained for up to two years, while Cohort 2 patients exhibited greater symptom relief and improved cardiac function at earlier time points, suggesting durable and dose-responsive effects of TN-201.
- Regulatory Progress: TN-201 has received PRIME designation from the European Medicines Agency and is included in the FDA's Rare Disease Evidence Principles process, with Tenaya planning to expand enrollment for further long-term outcome characterization, highlighting the company's strategic positioning in cardiac disease treatment.
See More
Tenaya Therapeutics Presents Interim Data on TN-201 Gene Therapy for HCM
- Clinical Trial Update: Tenaya Therapeutics is presenting new interim data from the MyPEAK-1 Phase 1b/2 trial for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, with a webcast scheduled for June 3, 2026, enhancing clinical transparency and investor confidence.
- Disease Context: MYBPC3-associated hypertrophic cardiomyopathy is the most common genetic form, accounting for about 20% of the 120,000 patients in the U.S., highlighting the widespread nature of the condition and its severe impact on patients' quality of life, with no effective treatments addressing its genetic cause.
- Therapeutic Mechanism: TN-201 is an AAV9-based gene therapy designed to deliver a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion, aiming to restore MyBP-C protein levels and potentially halt or reverse disease progression, which could have significant clinical implications.
- Market Performance: TNYA's stock has traded between $0.48 and $2.35 over the past year, closing at $0.79 on Tuesday with a 9.20% decline, while pre-market trading shows an increase to $0.84, up 6.33%, indicating market interest in its clinical advancements.
See More
Tenaya Therapeutics to Report Interim Data on TN-201 Gene Therapy for HCM
- Clinical Data Release: Tenaya Therapeutics will announce interim data from the MyPEAK™-1 trial on June 3, 2026, focusing on TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, potentially offering new treatment hope for 120,000 patients in the U.S.
- Live Webcast Event: The company will host a live webcast at 8:00 AM ET on the same day to review new data from MyPEAK™-1, allowing participants to register for access, thereby enhancing investor transparency and trust in the company's R&D progress.
- Disease Background: Variants in MYBPC3 are the leading genetic cause of hypertrophic cardiomyopathy, affecting approximately 20% of patients, leading to abnormal heart contraction and serious outcomes like heart failure and arrhythmias, indicating a strong market demand for TN-201.
- Therapy Design and Regulatory Progress: TN-201 is an AAV9-based gene therapy that has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug designations, highlighting its innovation and market potential in treating hypertrophic cardiomyopathy.
See More
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
